Canakinumab effective for Systemic Juvenile Idiopathic ArthritisA new interleukin-1 (IL-1)-beta blocking monoclonal antibody, Canakinumab (ACZ885), has shown encouraging effectiveness besides being well tolerated in children suffering with systemic juvenile idiopathic arthritis (sJIA).

This finding was revealed by a new phase II study presented at PReS 2009, a joint congress with the 2009 Congress of the European League against Rheumatism (EULAR) in Copenhagen, Denmark.

Dr Nicolino Ruperto, Senior Scientist of PRINTO (Paediatric Rheumatology International Trials Organization), an international not-for-profit research network managing trials of children with rheumatic diseases, said JIA (juvenile idiopathic arthritis) is the most common chronic inflammatory disease of childhood affecting nearly one in 1,000 children, and sJIA is the most severe subtype.